HeartBeam Inc. (NASDAQ: BEAT) has reported its second-quarter 2026 financial and operational results, highlighting significant strides in its heart attack detection program and initial commercial launch. The company completed enrollment of 134 patients in its ALIGN-ACS pilot study ahead of schedule, with full results expected to be presented at TCT 2026, and surpassed 50% enrollment in its 500-patient HEADSTART-ACS pilot study. These milestones are crucial as they move the company closer to bringing its innovative 3D ECG technology to market, potentially revolutionizing how heart attacks are detected and managed.
The company also completed a working prototype of its 12-lead ECG extended wear patch, signed multiple commercial agreements across four targeted U.S. geographies, shipped its first orders, and onboarded initial patients. This early commercial traction indicates growing interest in HeartBeam's technology, which aims to provide actionable cardiac intelligence outside of traditional medical facilities. The 12-lead ECG synthesis software received FDA clearance in December 2025, and the system is cleared for arrhythmia assessment, as detailed in the company's cleared indications for use.
Financially, HeartBeam reported a second-quarter net loss of $5 million, or $0.10 per basic and diluted share, consistent with the prior year's loss. Cash, cash equivalents, and restricted cash totaled $8.8 million as of June 30, 2026. The company expects full-year 2026 net operating cash outflow to be below $14 million, which, combined with its current cash position, extends its runway into 2027. This financial prudence is vital for a medical technology company in its early commercialization phase, ensuring it can fund ongoing clinical trials and product development.
The ALIGN-ACS and HEADSTART-ACS studies are pivotal for validating HeartBeam's technology in real-world settings. The ALIGN-ACS pilot, which has completed enrollment, will provide critical data on the accuracy of the 3D ECG in detecting acute coronary syndrome. The larger HEADSTART-ACS study aims to further solidify the clinical evidence. These studies are expected to support regulatory submissions and adoption by healthcare providers. According to the company, the technology has the potential to identify cardiac health trends and acute conditions, directing patients to appropriate care promptly, which could significantly improve outcomes for heart attack patients.
HeartBeam's platform technology is designed to be portable and user-friendly, allowing patients to record ECG signals in 3D from three non-coplanar directions, which are then synthesized into a 12-lead ECG. This innovative approach eliminates the need for cables and wires, making it possible for patients to use the device at home or anywhere, thus expanding access to cardiac monitoring. The company holds over 20 issued patents related to its technology, underscoring its intellectual property strength.
The company's recent progress, including the completion of the ALIGN-ACS pilot and the advancement of the HEADSTART-ACS study, is a testament to its execution capabilities. With a cash runway into 2027 and a clear path toward commercialization, HeartBeam is well-positioned to make a significant impact in the field of cardiac care. Investors and healthcare professionals will be watching closely as the company presents full ALIGN-ACS results at TCT 2026, which could be a pivotal moment for the company and its technology.
